Organ-on-a-chip technology has been used in testing small-molecule drugs for screening potential therapeutics and regulatory protocols. The technology is expected to boost the development of novel therapies and accelerate the discovery of drug combinations in the coming years. This has led to the development of multi-organ-on-a-chip (MOC) for recapitulating various organs involved in the drug–body interactions. In this review, we discuss the current MOCs used in screening small-molecule drugs and then focus on the dynamic process of drug absorption, distribution, metabolism, and excretion. We also address appropriate materials used for MOCs at low cost and scale-up capacity suitable for high-performance analysis of drugs and commercial high...
ABSTRACT: Direct detection and analysis of biomolecules and cells in physiological microenvironment ...
Introduction: The ever growing amount of new substances released to the market and the limited predi...
A low percentage of novel drug candidates succeed and reach the end of the drug discovery pipeline, ...
Organ-on-a-chip technology has been used in testing small-molecule drugs for screening potential the...
With advantageous features such as minimizing the cost, time, and sample size requirements, organ-on...
Development of predictive multi-organ models before implementing costly clinical trials is central f...
The development of new medicines suffers from attrition, especially in the development pipeline. Eig...
Organ-on-a-chip technology has the potential to accelerate pharmaceutical drug development, improve ...
Recent advances in biomedical technologies are mostly related to the convergence of biology with mic...
Patients around the world who suffer from a host of debilitating conditions rely on medications for ...
Multi-organ microdevices can mimic tissue-tissue interactions that occur as a result of metabolite t...
The development of cancer models that rectify the simplicity of monolayer or static cell cultures ph...
Drugs affect the human body through absorption, distribution, metabolism, and elimination (ADME) pro...
Organ-on-a-chip technology is used to study biological processes that involve multiple cell types an...
Direct detection and analysis of biomolecules and cells in physiological microenvironment is urgentl...
ABSTRACT: Direct detection and analysis of biomolecules and cells in physiological microenvironment ...
Introduction: The ever growing amount of new substances released to the market and the limited predi...
A low percentage of novel drug candidates succeed and reach the end of the drug discovery pipeline, ...
Organ-on-a-chip technology has been used in testing small-molecule drugs for screening potential the...
With advantageous features such as minimizing the cost, time, and sample size requirements, organ-on...
Development of predictive multi-organ models before implementing costly clinical trials is central f...
The development of new medicines suffers from attrition, especially in the development pipeline. Eig...
Organ-on-a-chip technology has the potential to accelerate pharmaceutical drug development, improve ...
Recent advances in biomedical technologies are mostly related to the convergence of biology with mic...
Patients around the world who suffer from a host of debilitating conditions rely on medications for ...
Multi-organ microdevices can mimic tissue-tissue interactions that occur as a result of metabolite t...
The development of cancer models that rectify the simplicity of monolayer or static cell cultures ph...
Drugs affect the human body through absorption, distribution, metabolism, and elimination (ADME) pro...
Organ-on-a-chip technology is used to study biological processes that involve multiple cell types an...
Direct detection and analysis of biomolecules and cells in physiological microenvironment is urgentl...
ABSTRACT: Direct detection and analysis of biomolecules and cells in physiological microenvironment ...
Introduction: The ever growing amount of new substances released to the market and the limited predi...
A low percentage of novel drug candidates succeed and reach the end of the drug discovery pipeline, ...